t expenses were $16.6 million for
the year ended December 31, 2007 and $7.3 million for the same period in
2006. Research and development expense increased $9.3 million in 2007
compared to 2006 primarily as a result of increased process development and
manufacturing activities related to Protexia(R) and Valortim(TM) of $9.2
million, and employee-related expenses, including stock compensation
expense of $1.8 million. These increases were partially offset by reduced
preclinical and clinical activities related mostly to the Valortim(TM)
clinical trial program.
General and administrative expenses for the Company in 2007 were $13.9
million compared to $8.5 million for the same period in 2006. The increase
in general and administrative costs in 2007 was attributable to increased
employee costs, a related increase in travel expense, increased stock
compensation expense, and increased facilities costs as PharmAthene
relocated its corporate headquarters in 2007 to larger facilities in
Annapolis.
PharmAthene's net loss attributable to common shareholders for the year
ended December 31, 2007 was $17.7 million or $1.88 per basic and diluted
share. Non-cash adjustments for the year ended December 31, 2007 included a
$2.4 million credit that resulted from the cancellation of former
PharmAthene preferred stock warrants, a $0.9 million gain on the
extinguishment of debt, and stock compensation expense of $1.7 million.
As of December 31, 2007, cash, cash equivalents and short term
investments were $52.7 million, compared to $5.1 million at December 31,
2006. The $47.6 million increase in cash, cash equivalents and short term
investments from December 31, 2006 is primarily attributable to the August
2007 merger with HAQ, which resulted in net cash proceeds of $57.9 million
and to the March 2007 $10.0 million credit facility, partially offset by
the funding of operations for fiscal year 2007.
On March 20, 2008, PharmAthene announced that the Company had sig
'/>"/>
SOURCE PharmAthene, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1.
Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.2.
Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court3.
PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services4.
Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA5.
PharmAthene to Present at the BIO CEO & Investor Conference 20086.
PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations7.
PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 20088.
PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference9.
PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia10.
PharmAthene to Delay Release of Full Year 2007 Financial Results11.
PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008